Danaher Corporation $DHR Shares Newly Acquired by Chapin Davis Inc.

Chapin Davis Inc. bought a new stake in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 4,319 shares of the conglomerate’s stock, valued at approximately $957,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Danaher during the 2nd quarter worth approximately $10,492,520,000. Jupiter Topco LLC purchased a new stake in shares of Danaher during the second quarter worth $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher in the second quarter valued at $1,287,949,000. Bank of America Corp DE acquired a new stake in shares of Danaher in the second quarter valued at $993,846,000. Finally, Legal & General Group Plc purchased a new position in Danaher in the second quarter valued at $801,056,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on DHR. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Evercore reissued an “outperform” rating and set a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. Barclays upped their target price on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday. UBS Group initiated coverage on shares of Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price on the stock. Finally, TD Cowen decreased their price target on shares of Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.23.

Danaher Price Performance

Shares of NYSE DHR opened at $217.33 on Friday. The stock’s 50-day simple moving average is $210.88 and its 200-day simple moving average is $194.44. The firm has a market capitalization of $152.78 billion, a PE ratio of 38.60, a price-to-earnings-growth ratio of 2.72 and a beta of 0.76. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.77 earnings per share. As a group, equities research analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.